Clinical Trial

A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia

Name: A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia — clinical trial record (NCT07681440)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Terminated

View on ClinicalTrials.gov →

Summary

The purpose of this study is to understand the patient profile, utilized treatments, treatment patterns, resulting outcomes, and associated costs relating to luspatercept treatment in patients with lower-risk myelodysplastic syndromes (LR-MDS) or beta-thalassemia in the real-world setting

Trial Details

NCT Number	NCT07681440
Lead Sponsor	Bristol-Myers Squibb
Conditions	Myelodysplastic Syndromes, Beta-thalassemia
Enrollment	30 participants
Start Date	2023-11-16
Primary Completion	2025-05-01 (estimated)
Study Completion	2025-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-02